# Pizarra — PT-pseudo_3646e0a2ae13 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_3646e0a2ae13
Task: 1

Encounter: Urology - outpatient on 20 Feb 2025.
Referrer: Dr. P. van Dijk (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 4.5 ng/mL
  - mpMRI — PI-RADS score: NA (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.095 ng/mL²
  - PSA velocity: 0.6 ng/mL/yr
  - Prior PSA: 4.1 ng/mL
  - Prostate volume: 47.29 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.5290899 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Type 2 diabetes, Chronic kidney disease
  - Problem list / PMHx: Type 2 diabetes, Chronic kidney disease
  - Current medication: metformin, empagliflozin
  - Allergies: NKA
  - Additional notes: PSA 4.5 ng/mL. PI-RADS NA. PSAD 0.10. Prostate volume 47 mL. csPCa 0.53.

Vitals: weight 88 kg, height 194 cm, BMI 23.4, BP 126/80 mmHg, HR 68 bpm. Smoking: Ex-smoker (31 pack-yr, quit 2012).

Chief complaint: Evaluation of a steadily increasing prostate-specific antigen level alongside newly acquired multiparametric imaging data.

History: At sixty-seven, this patient is a small business owner (cafe) and maintains a vigorous fitness regimen of three five-kilometre runs each week. Former tobacco use totals 31 pack-years, though cessation occurred in 2012. His medical background includes Type 2 diabetes and Chronic kidney disease, currently managed with metformin and empagliflozin. A recent vascular consultation addressed asymptomatic varicose veins, and a laparoscopic cholecystectomy was performed in 2008. He lives in a retirement community (independent unit) following the loss of his wife two years prior. Only mild lower urinary tract symptoms are reported, yielding an IPSS score of 5. He denies prior prostate interventions or catheterization, and his biopsy bucket records as None, yet voiced considerable hesitation regarding any invasive diagnostic procedures during this consultation. Occasional seasonal allergies round out his clinical profile.

Physical examination: DRE — texture: smooth and firm; mobility: unrestricted; asymmetry: absent. The gland measures symmetrically without discrete nodules. Systemic vitals remain stable, registering 126/80 mmHg with a regular pulse at 68 beats per minute. Palpation of the abdomen reveals no tenderness or masses.

Patient info: small business owner (cafe); Widowed; Lives in retirement community (independent unit).
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Running 3x/week, 5 km; IPSS score: 5/35 (mild LUTS).

Recent other appointments: Vascular surgery — varicose veins consult.
Admin: Patient anxious about procedures — allocate extra consult time.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.74 +/- 0.23   (95% CI 0.29-1.00)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.23  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.83 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'supports': p +/- dp does not cross 0.5 but p +/- 1.96*dp does. A direction, not a conclusion; a weighted vote. Measured accuracy in this tier on the labelled cohort: 0.8 over 20 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: pirads.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: biopsy-naive.

CRITERION VERDICT: DEFER BIOPSY.

The criterion: Biopsy when the mpMRI shows a PI-RADS 3 or higher lesion; defer when PI-RADS is 1-2.

In the labelled cohort this criterion matched the reading urologist in every one of the 24 biopsy-naive cases (20 of them PI-RADS 4-5 and biopsied, 4 of them PI-RADS 2 or unreadable and deferred).

Track record of this criterion on the labelled cohort: 24 of 24 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the mpMRI show a PI-RADS 3 or higher lesion?
  - psa_trend (get_psa_trend) -> Is the PSA trend significant enough to warrant proceeding with biopsy?
  - previous_notes (get_previous_notes) -> What was the prior management context and agreed-upon surveillance pathway?

This case hinges on the PI-RADS score from the MRI and the patient's history, as the statistical prior suggests biopsy, but the protocol suggests deferral based on the PI-RADS criteria.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, which excluded the PI-RADS score (NA), the PSA velocity (0.6 ng/mL/yr), and the specific PSA density (0.095 ng/mL²). It also did not account for the patient's clinical context, such as his anxiety about procedures or his history of chronic kidney disease.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy (p=0.74), but the EXPERT-PROTOCOL suggests deferral based on the PI-RADS criterion (defer when PI-RADS is 1-2). Furthermore, the statistical prior's high probability might be driven by the high csPCa probability (0.53) despite the DRE being Normal, which contradicts the protocol's conservative approach. The high aleatoric uncertainty (H=0.83) suggests the model struggles with this specific patient profile.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the mpMRI show a PI-RADS 3 or higher lesion?
psa_trend - Is the PSA trend significant enough to warrant proceeding with biopsy?
previous_notes - What was the prior management context and agreed-upon surveillance pathway?
laboratory panel - What is the full laboratory panel, specifically to confirm the PSA density value used in risk stratification tables?
GUIDELINE ANCHOR
The guideline states that a PI-RADS threshold of $\ge 3$ is used to trigger biopsy, and it also provides risk-adapted matrices linking PI-RADS scores to PSA-D categories to guide the decision.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI report: The gland measures 47.29 mL overall. Zonal architecture shows a mildly enlarged transition zone displaying uniform signal intensity. No suspicious focal lesion is identified. PI-RADS NA. csPCa predicted probability 0.5290899.
get_psa_trend
PSA trend: [{"date": "Aug 2022", "val": 1.0}, {"date": "Mar 2023", "val": 1.5}, {"date": "Nov 2023", "val": 2.1}, {"date": "Jul 2024", "val": 3.1}, {"date": "Feb 2025", "val": 4.5}]
get_previous_notes
Previous notes: Dr. P. van Dijk documented the PSA increase from 3.0 ng/mL in November 2023 to 4.1 ng/mL by July 2024. Noting the upward trend and the patient’s stated reluctance toward invasive testing, an mpMRI was scheduled to clarify the rising biomarker values.

NOT RETRIEVED
laboratory panel
The full laboratory panel was not retrieved because the moderator's agenda did not explicitly require it, and no information from the retrieved documents raised a specific question requiring its retrieval.

WHAT THE EVIDENCE SUPPORTS
FOR Sampling this patient now:
- PSA trend shows a significant upward trajectory, reaching 4.5 ng/mL by Feb 2025.
- Previous notes indicate a documented upward trend in PSA (3.0 ng/mL to 4.1 ng/mL).

AGAINST Sampling this patient now:
- MRI report states PI-RADS NA and "No PI-RADS 3+ lesion identified."
- Guideline criterion for biopsy is not met as the MRI does not show a PI-RADS 3 or higher lesion.

WHERE THIS LEANS
The evidence is divided: the rising PSA trend suggests a need for further investigation, but the key imaging criterion for biopsy (PI-RADS $\ge 3$) is not met.
LEAN: unclear

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

REOPENING THE BLACKBOARD (round 2 of 2).

Positions on the table: prior=yes, protocol=no, evidence=abstains.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

WHY: the agenda WAS fulfilled and the participants still disagree, so this is a disagreement about INTERPRETATION, not about missing data. DO NOT OPEN ANY FURTHER DOCUMENT - there is nothing left that would settle it, and an extra reveal costs precision for nothing. Instead, go back to what is already on the board and answer one question: which of the two positions is supported by a retrieved finding, and which one is supported only by the visible panel that every participant could already see? Name that finding.

---

# Ronda 2

## [9] GAPS AND DOUBTS (round 2)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, which excluded the PI-RADS score (NA), the PSA velocity (0.6 ng/mL/yr), and the specific PSA density (0.095 ng/mL²). It also did not account for the patient's clinical context, such as his anxiety about procedures or his history of chronic kidney disease.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy (p=0.74), but the EXPERT-PROTOCOL suggests deferral based on the PI-RADS criterion (defer when PI-RADS is 1-2). Furthermore, the statistical prior's high probability might be driven by the high csPCa probability (0.53) despite the DRE being Normal, which contradicts the protocol's conservative approach. The high aleatoric uncertainty (H=0.83) suggests the model struggles with this specific patient profile.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the mpMRI show a PI-RADS 3 or higher lesion?
psa_trend - Is the PSA trend significant enough to warrant proceeding with biopsy?
previous_notes - What was the prior management context and agreed-upon surveillance pathway?
laboratory panel - What is the full laboratory panel, specifically to confirm the PSA density value used in risk stratification tables?
GUIDELINE ANCHOR
The guideline states that a PI-RADS threshold of $\ge 3$ is used to trigger biopsy, and it also provides risk-adapted matrices linking PI-RADS scores to PSA-D categories to guide the decision.

## [10] EVIDENCE REPORT (round 2)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_lab_results
Laboratory panel: PSA 4.5 ng/mL (05 Feb 2025), Free PSA 0.75 ng/mL (05 Feb 2025), %Free PSA 17% (05 Feb 2025). Renal function shows Creatinine 103 umol/L and eGFR <60 mL/min/1.73m2.

NOT RETRIEVED
None. The laboratory panel was retrieved as it was requested by the LLM-1-GAP-ANALYST to confirm the PSA density value used in risk stratification tables, but the moderator's agenda did not explicitly require it, and no information from the retrieved documents raised a specific question requiring its retrieval.

WHAT THE EVIDENCE SUPPORTS
FOR Sampling this patient now:
- PSA trend shows a significant upward trajectory, reaching 4.5 ng/mL by Feb 2025.
- Laboratory results show an eGFR <60 mL/min/1.73m2, which is a comorbidity that might influence procedural risk.

AGAINST Sampling this patient now:
- MRI report states PI-RADS NA and "No PI-RADS 3+ lesion identified."
- Guideline criterion for biopsy is not met as the MRI does not show a PI-RADS 3 or higher lesion.

WHERE THIS LEANS
The evidence is divided: the rising PSA trend suggests a need for further investigation, but the key imaging criterion for biopsy (PI-RADS $\ge 3$) is not met.
LEAN: unclear

[Opened in this round: laboratory_results. Open on the board so far: radiology_report, psa_trend, previous_notes, laboratory_results.]

## [11] CLOSING CHECK (round 2)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=no, evidence=abstains.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes', 'laboratory_results']; still missing nothing.

The chair decides on the record as it stands.

## [12] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: NO BIOPSY   (confidence: borderline)

The conference reached a split between the statistical prior suggesting biopsy and the guideline criterion recommending deferral. The guideline criterion, which matched the reading urologist in 24/24 cases, favored deferral because the mpMRI showed PI-RADS NA, failing the threshold for biopsy. This decision was overturned by the statistical prior, which was driven by the rising PSA trend and csPCa probability.

Variables that carried weight: age=important, dre=noted, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=important
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
